Ofloxacin Use in Pediatric Patients: Evidence‑Based Guidance

Topical Otic Application

Ofloxacin otic 0.3 % solution is safe and effective for acute otitis externa and tympanostomy‑tube‑associated otorrhea in children as young as 6 months; the recommended regimen is 5 drops in the affected ear(s) once or twice daily for 7–10 days, providing high clinical cure rates while avoiding systemic absorption and cartilage toxicity concerns. 1

The Centers for Disease Control and Prevention (CDC) recommends for children 1 month to ≤ 17 years with plague (treatment or prophylaxis) a dose of 7.5 mg/kg orally every 12 hours (maximum 400 mg per dose). [2][3]4
In CDC guidance, ofloxacin is listed as an alternative agent (not first‑line) for pediatric plague; ciprofloxacin and levofloxacin are preferred fluoroquinolones. [2][3]4
Oral suspension of ofloxacin is not commercially available in the United States, so tablets must be compounded if systemic therapy is required. [2][3]

The Clinical Infectious Diseases (CID) guidelines advise that ofloxacin should be avoided for community‑acquired pneumonia and other common pediatric infections; instead, age‑appropriate β‑lactams or macrolides are recommended as first‑line therapy. [5][6][7][8]
Fluoroquinolones, including ofloxacin, are not considered first‑line agents for typical pediatric respiratory infections according to CID. [6][5]

Fluoroquinolone resistance among pediatric isolates remains low (generally < 5 % for most gram‑negative organisms), though higher rates are observed in cystic fibrosis patients. 1
Off‑label systemic use of ofloxacin in children may be considered when the therapeutic benefit outweighs the potential risk, particularly for serious infections lacking adequate alternatives. 1